Monday, 4 December 2017

CSL Behring Advances to Phase 3 Cardiovascular Outcomes Trial for CSL112, its Novel Apolipoprotein AI (Human ...

  1. CSL Behring Advances to Phase 3 Cardiovascular Outcomes Trial for CSL112, its Novel Apolipoprotein AI (Human ...  PR Newswire (press release)Full coverage
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)